ACQT1127 >

ACQT1127 >

ACQT1127 is the Acquist clinical lead.  As of Q2 2019, the drug had cleared in vitro screening and had entered animal toxicology studies.  ACQT1127 is a potent inhibitor of xanthine oxidase (approximately 70 time more potent than allopurinol, as well as a potent inhibitor of URAT1.  It is the only drug in clinical development that exhibited this bifunctional activity.

Clinical proof-of-concept with our drugs was established with a prototype (ACQT1001) that showed marked reduction of serum uric acid in all patients who received that agent.  ACQT1127 is a derivative of that drug that has superior enzymatic activity, increased safety, favorable pharmacokinetics, and oral bioavailability that will enable once-daily oral dosing.

The Company will request a pre-IND meeting to discuss technical and development plans with the Food and Drug Administration (FDA) prior to IND submission in the U.S.

ACQT1127 is the Acquist clinical lead.  As of Q2 2019, the drug had cleared in vitro screening and had entered animal toxicology studies.  ACQT1127 is a potent inhibitor of xanthine oxidase (approximately 70 time more potent than allopurinol, as well as a potent inhibitor of URAT1.  It is the only drug in clinical development that exhibited this bifunctional activity.

Clinical proof-of-concept with our drugs was established with a prototype (ACQT1001) that showed marked reduction of serum uric acid in all patients who received that agent.  ACQT1127 is a derivative of that drug that has superior enzymatic activity, increased safety, favorable pharmacokinetics, and oral bioavailability that will enable once-daily oral dosing.

The Company will request a pre-IND meeting to discuss technical and development plans with the Food and Drug Administration (FDA) prior to IND submission in the U.S.

ACQT1127 is the Acquist clinical lead.  As of Q2 2019, the drug had cleared in vitro screening and had entered animal toxicology studies.  ACQT1127 is a potent inhibitor of xanthine oxidase (approximately 70 time more potent than allopurinol, as well as a potent inhibitor of URAT1.  It is the only drug in clinical development that exhibited this bifunctional activity.

Clinical proof-of-concept with our drugs was established with a prototype (ACQT1001) that showed marked reduction of serum uric acid in all patients who received that agent.  ACQT1127 is a derivative of that drug that has superior enzymatic activity, increased safety, favorable pharmacokinetics, and oral bioavailability that will enable once-daily oral dosing.

The Company will request a pre-IND meeting to discuss technical and development plans with the Food and Drug Administration (FDA) prior to IND submission in the U.S.

 

ACQT1127 is the Acquist clinical lead.  As of Q2 2019, the drug had cleared in vitro screening and had entered animal toxicology studies.  ACQT1127 is a potent inhibitor of xanthine oxidase (approximately 70 time more potent than allopurinol, as well as a potent inhibitor of URAT1.  It is the only drug in clinical development that exhibited this bifunctional activity.

Clinical proof-of-concept with our drugs was established with a prototype (ACQT1001) that showed marked reduction of serum uric acid in all patients who received that agent.  ACQT1127 is a derivative of that drug that has superior enzymatic activity, increased safety, favorable pharmacokinetics, and oral bioavailability that will enable once-daily oral dosing.

The Company will request a pre-IND meeting to discuss technical and development plans with the Food and Drug Administration (FDA) prior to IND submission in the U.S.

Copyright © 2021 Acquist Theraputics, Inc.®